Alpha Cognition Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Alpha Cognition Inc. (ACOG) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 6.27 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- Alpha Cognition Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 6.27M shares, a 4.54% increase year-over-year.
- Alpha Cognition Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 5.55M shares, a 6.78% decline year-over-year.
- Alpha Cognition Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 4.49M shares, a 4.77% increase year-over-year.
- Alpha Cognition Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 6.00M shares.
- Alpha Cognition Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 5.68M shares, a 32.33% increase from fiscal 2024.
- Alpha Cognition Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 4.29M shares, a 50.59% increase from fiscal 2023.
- Alpha Cognition Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 2.85M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 6.27M shares 10-Q · filed 2026-08-13 | 5.85M shares 10-Q · filed 2026-08-13 | |||||
| 2026-03-31 | 5.55M shares 10-Q · filed 2026-05-14 | ||||||
| 2025-12-31 | 5.68M shares 10-K · filed 2026-03-31 | ||||||
| 2025-09-30 | 4.49M shares 10-Q · filed 2025-11-13 | 5.01M shares 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | 6.00M shares 10-Q · filed 2026-08-13 | 6.00M shares 10-Q · filed 2026-08-13 | |||||
| 2025-03-31 | 5.96M shares 10-Q · filed 2026-05-14 | ||||||
| 2024-12-31 | 4.29M shares 10-K · filed 2026-03-31 | 4.70M shares 10-K · filed 2025-03-31 | |||||
| 2024-09-30 | 4.29M shares 10-Q · filed 2025-11-13 | 4.29M shares 10-Q · filed 2025-11-13 | 4.29M shares 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | 3.53M shares 10-Q · filed 2025-08-14 | 88.37M shares 10-Q · filed 2024-08-12 | |||||
| 2024-03-31 | 3.56M shares 10-Q · filed 2025-05-15 | ||||||
| 2023-12-31 | 2.85M shares 10-K · filed 2025-03-31 | ||||||
| 2023-09-30 | 2.39M shares 10-Q · filed 2024-11-14 | ||||||
| 2023-06-30 | 66.99M shares 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |